Executive Chair Steven Hoerter Loses Independent Status, Resigns from Audit Committee

summarizeSummary

MBX Biosciences updated its proxy statement, announcing that Executive Chair Steven L. Hoerter is no longer an independent director due to a new consulting agreement, leading to his resignation from the Audit Committee.

check_boxKey Events

• Executive Chair's Independence Status Changed

  Steven L. Hoerter, Executive Chair, is no longer considered an independent director under Nasdaq rules following a new consulting agreement with the company, effective May 1, 2026.

• Resignation from Audit Committee

  As a direct consequence of his reclassification, Mr. Hoerter resigned from the Audit Committee, effective May 1, 2026.

• New Audit Committee Appointment

  Edward T. Mathers, an existing board member, was appointed to the Audit Committee, effective May 1, 2026.

• Equity Grants for Consulting Services

  In connection with the consulting agreement, Mr. Hoerter received a grant of 74,249 nonqualified stock options with an exercise price of $29.78 and 11,938 restricted stock units.

auto_awesomeAnalysis

This DEFA14A supplements the definitive proxy statement, detailing significant governance changes. Executive Chair Steven L. Hoerter entered into a consulting agreement with the company, leading to his reclassification as a non-independent director under Nasdaq rules and his resignation from the Audit Committee. This shift in independence for a key executive, particularly one serving as Executive Chair, is a notable governance development. While the consulting agreement and associated equity grants (74,249 options and 11,938 restricted stock units) were likely disclosed in the recent 10-Q, this filing formalizes the governance implications for the upcoming annual meeting. Edward T. Mathers was appointed to the Audit Committee to fill the vacancy.